Henan Cancer Hospital: Carcinoma, Non-Small-Cell Lung trials

The registry lists 15 Carcinoma, Non-Small-Cell Lung studies with Henan Cancer Hospital as lead sponsor. 11 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 3Phase 2 9Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Anlotinib in Cross-line Treatment of NSCLC and SCLCNot yet recruitingNCT07400575
• Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment FailureNot yet recruitingNCT06786208
• Local Injection and Systemic Therapy in the Treatment of NSCLC.Not yet recruitingNCT06618391Phase 2
• Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLCNot yet recruitingNCT06465238Phase 2
• Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06454890Phase 1/2
• An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung CancerRecruitingNCT06436885Early Phase 1
• Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung CancerRecruitingNCT06406608Not applicable
• the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With TrilaciclibEnrolling by invitationNCT06370416Phase 2
• Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment FailureRecruitingNCT06334757Phase 2
• Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)RecruitingNCT06231680Phase 2
• AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung CancerRecruitingNCT05377658Phase 2
• An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLCStatus unknownNCT05252091Phase 2
• Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLCStatus unknownNCT04331626Phase 4
• Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung CancerStatus unknownNCT04199559Phase 1/2
• Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLCStatus unknownNCT03790228Phase 1